Staphylocoagulase (SC)
3 is the prototype of a newly established zymogen activator and adhesion protein family (1) . SC nonproteolytically activates the blood coagulation zymogen, prothrombin (ProT) through interactions localized to the N-terminal 324 residues, and the SC-(1-325)⅐(pro)thrombin catalytic complex recognizes and cleaves fibrinogen (Fbg) as a specific substrate (2) (3) (4) . The C-terminal region of SC contains five to eight 27-residue repeat sequences that mediate distinctly different Fbg binding interactions (5) . Binding of C-terminal regions of SC to Fbg may localize the active SC⅐ProT complex to the platelet surfaces through Fbg bound to ␣IIb␤3 integrin (6) .
The recently determined crystal structure of a functional N-terminal fragment of SC (SC-(1-325)) bound to the catalytic domain of ProT, prethrombin 2 (Pre 2) (1) provided the first structural proof of the "molecular sexuality" mechanism of zymogen activation (7) . The N terminus of SC is bound to the "Ile 16 pocket" (chymotrypsinogen numbering) of Pre 2, presenting Ile 1 -Val 2 residues of SC to Asp 194 of Pre 2 and resulting in formation of the salt bridge necessary for proper serine proteinase folding and catalytic activity. SC-(1-325) is a boomerangshaped molecule that consists primarily of two three-helix bundle domains. The N-terminal domain (D1) of SC-(1-325) interacts with the 148 loop of Pre 2, positioning the N terminus for insertion into the Ile 16 pocket, whereas the second domain (D2) binds to (pro)exosite I on thrombin, Pre 2, and ProT (1) . The SC⅐(pro)thrombin complex cleaves Fbg specifically to generate fibrin clots in a process that is thought to contribute to the pathology of Staphylococcus aureus in human diseases such as pulmonary infections (8) and acute bacterial endocarditis (9) . Fbg recognition and cleavage by the SC-(1-325)⅐(pro)thrombin complexes and studies of full-length SC (10) or C-terminal regions of SC (6) indicate that there are two distinct modes of Fbg binding. The two distinct modes of interaction with Fbg may localize the SC⅐(pro)thrombin complexes pathophysiologically and mediate specific Fbg cleavage, although the relationship between these interactions is unknown.
The procoagulant and anticoagulant specificity of ␣-thrombin is linked to the expression of exosite I (11) (12) (13) (14) (15) , which directs specific recognition of numerous macromolecular substrates (factor V (16 -18) , factor VIII (16), Fbg (19) , and proteinase-activated receptors (20, 21) ), inhibitors (hirudin (15, 22) and heparin cofactor II (23, 24) ), and regulatory proteins (thrombomodulin (25) and fibrin (19, 26) ). Substrate specificity studies of SC⅐(pro)thrombin complexes indicate a highly restricted specificity for Fbg. The SC complexes do not cleave other physiological thrombin substrates, including factor V, factor VIII, or proteinase-activated receptors (3, 27) . SC binding to (pro)thrombin imparts resistance to the serpin inhibitors of thrombin, antithrombinheparin (3, 28) , and heparin cofactor II. 4 Because SC⅐(pro)thrombin complexes cleave Fbg specifically with D2 of SC occupying (pro)exosite I, Fbg substrate recognition must occur through a different site. A detailed structural analysis of the interfaces of D1 and D2 of SC-(1-325) with ProT and prediction of the mode of Fbg recognition by the SC-(1-325)⅐(pre)thrombin complexes are presented in the accompanying paper (29) .
To quantitate binding of SC- to ProT and binding of Fbg (29), we developed novel active site-labeled fluorescent analogs of the ProT zymogen as probes of the interactions. 5 The analogs are based on the reversibility of SC-induced ProT activation, which allows irreversible inactivation of the catalytic site of the zymogen by hemiketal formation with Ser 195 , generating prethrombin 1 (Pre 1) and fragment 1 and generating Pre 2Ј and fragment 2, respectively. D1 binding to labeled ProT accounted primarily for the fluorescence enhancement observed upon SC-(1-325) binding, whereas the affinity of the isolated D2 for ProT was ϳ130-fold greater than that of D1. SC-(1-325) complexes with thrombin and ProT exhibited equivalent Fbg clotting activities, only small differences in specificity for tripeptide chromogenic substrates compared with free thrombin, and no preference for the sequences preceding the cleavage sites for release of fibrinopeptides A and B. The blockage of exosite I-dependent Fbg clotting activity by SC-(1-325) and the small changes in tripeptide substrate specificity suggest that Fbg recognition is mediated by an exosite on the complex. Further studies of the Fbg interaction are presented in the companion paper (29) .
EXPERIMENTAL PROCEDURES
Protein Purification and Characterization-ProT was purified from human plasma (30) . ␣-Thrombin was active site-titrated by previously described methods (30) . The proteins were pure as determined by SDS gel electrophoresis. The protein concentrations were determined by absorbance at 280 nm with the following absorption coefficients ((mg/ ml) Ϫ1 cm
Ϫ1
) and molecular weights (31, 32) : ProT, 1.47, 71,600; thrombin, 1.74, 36,600; Fbg, 1.54, 340,000; Met-SC-(1-325) and SC-(1-325), 1.00, 38,000; D1, 1.42, 17,562 (calculated); D2, 0.64, 20,398 (calculated); and Met-SC-(1-325)-His 6 , 0.96, 39,461 (calculated). Absorption coefficients for SC species were calculated from the aromatic amino acid composition (33) .
Recombinant Staphylocoagulase- and Fusion Proteins-Met-SC-(1-325) and SC-(1-325) were expressed, purified, and characterized as described previously (1) . Met-SC-(1-325) fused to a C-terminal His 6 tag (Met-SC-(1-325)-His 6 ) was prepared by deleting a stop codon, which allowed translation of additional Lys-Leu-Ala-Ala-Ala-Leu-GluHis 6 residues. Met-SC-(1-325)-His 6 was expressed in Escherichia coli strain BL21(DE3) plysS. The cells were grown to an optical density of 0.4 -0.6 at 600 nm and induced by the addition of 500 M isopropyl-␤-D-thiogalactopyranoside. The cells were induced for 4 -6 h and lysed by three rounds of consecutive freeze-thaw cycles or sonication, and Met-SC-(1-325)-His 6 was purified from the soluble fraction after centrifugation, by Ni 2ϩ -iminodiacetic acid-Sepharose chromatography. Met-SC-(1-325)-His 6 activated ProT, as measured by H-D-Phe-PipArg-p-nitroanilide assay, with comparable activity as determined previously for Met-SC-(1-325) (1). Met-SC-(1-325)-His 6 was used instead of Met-SC-(1-325) in ProT labeling to facilitate separation of the activator and labeled zymogen.
Preparation of Active Site-labeled ProT Analogs-The thrombin-selective thioester-peptide chloromethyl ketone, ATA-FPR-CH 2 Cl, was prepared as described previously (30, 34) , and labeling followed a protocol similar to that described previously for streptokinase (SK)-mediated fluorescence labeling of plasminogen (35) . The Met-SC-(1-325)⅐ProT complex was inactivated by adding 145-200 M ATA-FPR-CH 2 Cl to 45-60 M ProT in 50 mM Hepes, 110 mM NaCl, 5 mM CaCl 2 , 1 mg/ml polyethylene glycol 8000, pH 7.4 buffer (Buffer A) at 25°C. Inhibition reactions were initiated by the addition of 90 -120 M Met-SC-(1-325) and were monitored by the decrease in the rate of hydrolysis of H-D-Phe-Pip-Arg-pNA. The reactions were typically complete (Ͻ0.1% activity) within 1 h. To ensure complete inhibition, 200 M FPR-CH 2 Cl was added. Excess inhibitor was removed by Sephadex G-25 chromatography in 0.1 M Hepes, 0.1 M NaCl, 5 mM CaCl 2 , pH 7.0 buffer. Met-SC-(1-325)⅐ATA-FPR-ProT (10 -25 M) was labeled by the addition of a 10-fold molar excess of the desired thiol-reactive probe derivative and subsequent addition of 0.1 M NH 2 OH, followed by incubation for 1-2 h in the dark at 25°C. Excess label was removed by Sephadex G-25 chromatography. Met-SC-(1-325)-labeled ProT complex was concentrated and dissociated by dialysis against Buffer A with 3 M NaSCN but without polyethylene glycol 8000. The dissociated proteins were separated by fast protein liquid chromatography gel filtration chromatography on 2-3 tandem Superdex 200 HR 10/30 columns equilibrated with the same buffer. Fractions containing the first of two overlapping peaks, consisting primarily of labeled ProT, were pooled and dialyzed against 50 mM Hepes, 125 mM NaCl buffer, pH 7.4 (Buffer B). The pooled protein was rechromatographed on Superdex 200 HR 10/30 in Buffer B under the same conditions. Fractions containing the second of two peaks, consisting of labeled ProT, were pooled, quickfrozen, and stored at Ϫ70°C.
A second, improved method was subsequently used for separation of labeled ProT from the Met-SC-(1-325)-labeled ProT complex using Met-SC-(1-325)-His 6 . The Met-SC-(1-325)-His 6 ⅐ProT complex was formed, inactivated, and labeled, and excess probe was removed as described above. Met-SC-(1-325)-His 6 ⅐labeled ProT was chromatographed on Ni 2ϩ -iminodiacetic acid-Sepharose in Buffer B. Labeled ProT was step-eluted with 3 M NaSCN, and the majority of Met-SC-(1-325)-His 6 was eluted with a gradient of imidazole up to 500 mM. Trace amounts of Met-SC-(1-325)-His 6 -labeled ProT complex were removed by fast protein liquid chromatography gel filtration on Superdex 200 HR 10/30 in Buffer B. Two peaks corresponding to Met-SC-(1-325)-His 6 -labeled ProT complex and free labeled ProT were eluted, and the labeled analog was pooled, dialyzed against Buffer B, quick-frozen, and stored at Ϫ70°C.
Characterization of Labeled ProT-The stoichiometry of fluorescence probe incorporation into ProT for 5-(iodoacetamido)fluorescein (5F), 2-((4Ј-iodoacetamido)anilino)naphthalene-6-sulfonic acid (ANS), and Oregon Green 488 iodoacetamide or 5-(and 6)-iodoacetamido-2Ј,7Ј-difluorofluorescein (OG) was determined from the absorbance at 280 nm and the corresponding probe absorbance in 0. [ Fbg Clotting Assays-Fbg clotting assays were performed at 37°C with a fibrometer (40) . Relative clotting activity was determined by comparison with an ␣-thrombin standard from the slopes of plots of clotting time against the reciprocal of the enzyme concentration. Hir-(54 -65)(SO 3 Ϫ ) was used at 20 M as an exosite I-specific inhibitor (19) .
OG]FPR-ProT Fluorescence Emission Spectra-[OG]FPR-ProT
Chromogenic Substrate Kinetics-Kinetic parameters for hydrolysis of chromogenic substrates by ␣-thrombin and SC-(1-325)⅐ (pro)thrombin were determined by monitoring the absorbance increase at 405 nm in Buffer A containing 1 mg/ml bovine serum albumin and 0.1 mg/ml soybean trypsin inhibitor at 25°C, using polyethylene glycol 20,000-coated cuvettes. For substrates with low K m , H-D-Phe-Pip-ArgpNA, H-D-Ile-Pro-Arg-pNA, and H-D-Phe-Pro-Arg-pNA, the kinetic parameters, k cat , K m and when applicable, K i , were determined by simultaneous fits of the integrated Michaelis-Menten equation (including competitive product inhibition) to the full reaction progress curves for conversion of substrate at concentration ranges of 0.9 -1, 4 -5, 8 -10, and 17-20 M by 0.5 nM enzyme and 60 M by 5 nM enzyme for each substrate. For Gly-Val-Arg-pNA, Ser-Ala-Arg-pNA, and CH 3 -Gly-GlyArg-pNA, the kinetic parameters were determined by fitting the Michaelis-Menten equation to initial rates collected over a substrate concentration range of 0 -6 mM. In all of the assays, SC-(1-325) and (pro)thrombin were preincubated for at least 20 min, and the reactions were initiated by the addition of substrate. Because the complex-dependent proteolysis described below is minimized at the concentrations used in the kinetic studies, there was no variation of the initial rates beyond the 20-min preincubation time.
RESULTS
Active Site Labeling of ProT-Active site-labeled fluorescent analogs of ProT were prepared as novel probes of SC-induced ProT activation and Fbg substrate recognition (Fig. 1A and the accompanying paper (29) ). The catalytic site induced by Met-SC-(1-325) binding to ProT was inactivated by hemiketal formation with Ser 195 and His 57 alkylation with the thioester-peptide chloromethyl ketone, ATA-FPR-CH 2 Cl (30, 34, 35, 41) . Subsequent generation of the free thiol by treatment with NH 2 OH, and probe incorporation by reaction with a thiol-reactive fluorescence probe yielded the labeled ProT zymogen. Specificity of ProT labeling was examined by determining the dependence of fluorescence probe incorporation on each of the steps in the reaction scheme (Fig.  1A) , as seen by fluorescence (Fig. 1B) and protein staining (Fig. 1C) on SDS gels. The protein bands of SC-(1-325) and ProT are seen as individual bands on the gels because the complex dissociates in SDS. The reaction in lane 1 showed that without SC-(1-325) no probe was incorporated because of the lack of zymogen activation. The reaction in lane 6 showed that the absence of NH 2 OH prevented probe incorporation, indicating the need for the free thiol. Blocking of the catalytic site in the Met-SC-(1-325)⅐ProT complex with FPR-CH 2 Cl before reaction with ATA-FPR-CH 2 Cl also blocked probe incorporation, demonstrating the requirement for reaction of the inhibitor with the activated zymogen ( Fig. 1, B and C, lane 7) . The results demonstrated specific labeling of the SC-activated catalytic site of the ProT zymogen. Preparation of a Met-SC-(1-325)-His 6 construct allowed separation of labeled ProT from SC-(1-325) based on the high affinity of His 6 for Ni 2ϩ -iminodiacetic acid under dissociating conditions (3 M NaSCN) and purification of the labeled analog (Fig. 1, B and C, lane 8) . Stoichiometries of probe incorporation into the isolated zymogen were 0.82-0.98 mol probe/mol of ProT for ANS, 5F, and OG. Preparations of labeled ProT had residual activities of 1-3%, determined by the activity generated with excess SC-(1-325).
Screening of ProT Analogs for Signals Accompanying SC-(1-325) Binding-An array of ProT analogs containing 10 fluorescence probes with various fluorescence spectral properties was prepared. The results of fluorescence titrations with SC-(1-325) are grouped by similar probe structures in Fig. 2 . SC-(1-325) titrations of 50 -285 nM labeled ProT indicated that SC-(1-325) bound ProT with a 0.84 -1.00 stoichiometry for those that could be determined (ACR, AF350, BD, 4ЈF, 5F, OG, and TMR). The K D values were poorly defined in these single titrations because of the apparent, very high affinity in relation to the labeled ProT concentrations. The signs and amplitudes of the fluorescence changes accompanying SC-(1-325) binding were dependent on the structures and spectral properties of the probes with no obvious correlation with polarity sensitivity (Fig. 2) . Interestingly, the polarity-sensitive probes, ACR and BAD, the adducts of which differ only by a methylene group in the linker, showed a 62% enhancement and essentially no change, respectively ( Fig. 2A) .
Quantitation of SC-(1-325) Binding to [OG]FPR-ProT and [5F]FPR-
ProT-All of the high quantum yield fluorescein-ProT derivatives, OG, 5F, and 4ЈF, showed large fluorescence enhancements of 95, 38, and 50%, respectively, at saturating SC-(1-325) (Fig. 2B) . (Fig. 3A) . These results were confirmed by analysis of similar titrations of 0.075, 0.25, 2.5, 10, and 100 nM [5F]FPR-ProT, indicating binding of SC-(1-325) to 0.96 Ϯ 0.05 mol sites/mol of ProT with a K D of 37 Ϯ 1 pM and a maximal fluorescence enhancement of 39 Ϯ 1% (Fig. 3B) .
Proteolytic Cleavage of ProT in the Presence of SC-(1-325)-
To determine the proteolytic stability of the SC-(1-325)⅐ProT complex, we incubated [OG]FPR-ProT with fixed or varied levels of SC-(1-325), in the presence of inhibitors, and with native ProT in the presence and absence of inhibitors and analyzed the products by fluorescence and protein staining on SDS gels. Fig. 4 shows the time course of ProT conversion to Pre 1 and Pre 2 in a mixture of labeled and native ProT (4 M each) and SC-(1-325) (8 M). Although cleavage was not complete, there was significant production of Pre 2 over the 4-h incubation. Fig. 5 (A and B) shows the results for mixtures of a preparation of [OG]FPR-ProT that had Ͻ2% residual native ProT activity, incubated with increasing concentrations of SC-(1-325) in the presence of 10 M FPR-CH 2 Cl. Labeled ProT in the absence and presence of SC-(1-325) was stable for up to 18 h in the dark at 25°C (Fig. 5, A and B) . In the presence of native ProT and in the absence of inhibitors, however, both native and labeled ProT were increasingly cleaved as a function of the SC-(1-325)⅐native ProT complex concentration (Fig. 5, C and D) , as evidenced by the similar staining pattern seen by fluorescence (Fig. 5C ) and protein staining (Fig. 5D) . Cleavage was essentially complete in mixtures of 3-6 M (Fig. 5, C and  D, lanes 6 and 7) . It was also evident that the SC-(1-325)⅐native ProT complex cleaved native and [OG]FPR-ProT bound to SC-(1-325) because in mixtures incubated for Ͼ16 h at concentrations of SC-(1-325) saturating labeled and native ProT (Fig. 5C, lanes 7 and 8) , essentially complete cleavage was observed. ProT cleavage in a mixture of labeled and native ProT (2 M each) and saturating SC-(1-325) (12 M) was completely inhibited by 100 M FPR-CH 2 Cl and 100 M AEBSF (Fig. 5, C and D, lane 9) . Free ProT was also cleaved at a much slower rate by the SC-(1-325)⅐native ProT complex than the ProT molecules bound to SC-(1-325) (data not shown). Two major fluorescent reaction product bands were identified as Pre 1 and Pre 2Ј by comparison of similar reactions with purified ProT activation species (not shown). Pre 2Ј is formed by thrombin cleavage of ProT at Arg 284 -Thr 285 , resulting in a form of Pre 2 that is 13 residues shorter (42) . N-terminal sequencing of the polyvinylidene difluoride membrane-blotted reaction product confirmed the N-terminal sequence of Thr-Phe-Gly-Ser-Gly, corresponding to Pre 2Ј. (Fig. 6 ). There were no significant differences between the curves generated by the cubic binding equation when the stoichiometric factor was fit (Fig. 6, solid lines) or fixed at 1 (dashed lines). These results were in good agreement with the dissociation constants of 37 Ϯ 1 and 17 Ϯ 6 pM determined for direct binding of SC-(1-325) to [5F]FPRProT and [OG]FPR-ProT (Fig. 3) and indicated that native and labeled ProT bound SC-(1-325) with indistinguishable affinity.
Binding of SC-(1-325) to Native ProT-To
Binding of D2 to (Pro)exosite I on ProT-To determine whether the lack of SC cofactor activity exhibited by D2 (1) (Fig. 7 ) of D2 to ProT gave a dissociation constant of 40 Ϯ 90 nM and a 1.0 Ϯ 0.1 mol D2/mol of ProT stoichiometry. These results indicated that D2 folds independently of D1 and that the isolated D2 domain binds to proexosite I on ProT in a similar fashion as SC-(1-325). To our knowledge, this is the highest affinity proexosite I interaction for a protein ligand to date. (Table 1) . Although thrombin was almost totally inhibited (88%) by Hir-(54 -65)(SO 3 Ϫ ) binding to exosite I, the peptide had a negligible effect (5%) on the clotting activities of SC-(1-325)⅐␣-thrombin and Met-SC-(1-325)⅐␣-thrombin, and a small (22%) effect on the corresponding ProT complexes.
Binding of Isolated Domains of SC-(1-325) to [OG]FPR-ProT-To
Effect of SC-(1-325) on the Specificity of (Pro)thrombin for Tripeptide Chromogenic Substrates-To assess differences in substrate specificity of ␣-thrombin and SC-(1-325)⅐(pro)thrombin complexes, MichaelisMenten kinetic parameters were determined for a panel of six tripeptide-pNA substrates. The SC-(1-325)⅐␣-thrombin complex showed a ϳ2-fold decrease in k cat compared with free ␣-thrombin for hydrolysis of the tight binding substrates, H-D-Phe-Pip-Arg-pNA, H-D-Ile-ProArg-pNA, and D-Phe-Pro-Arg-pNA (Table 2) . Kinetic parameters K m and K i for product were remarkably similar for ␣-thrombin, SC-(1-325)⅐␣-thrombin, and SC-(1-325)⅐ProT complexes for these tight substrates with the exception of a 40-fold higher affinity for the product of D-Phe-Pro-Arg-pNA cleavage for SC-(1-325)⅐␣-thrombin compared with ␣-thrombin or SC-(1-325)⅐ProT. To determine whether SC-(1-325) binding affected hydrolysis of substrates based on the P1-P3 6 cleavage sequences for fibrinopeptides A and B, Ser-Ala-Arg-pNA and GlyVal-Arg-pNA were examined. SC-(1-325)⅐␣-thrombin complex showed a ϳ2-fold increase in k cat for both substrates compared with free ␣-thrombin, whereas there were no consistent changes for SC-(1-325)⅐ProT complex ( Table 2 ). The combined kinetic data indicated that the SC-(1-325)⅐␣-thrombin complex displayed only small ϳ2-fold increases or decreases in k cat compared with ␣-thrombin. generated an ␣-thrombin-like substrate recognition site for tripeptidepNA substrates, with small but reproducible effects on k cat for hydrolysis of certain substrates, and no significant preference for substrates based on the sequences preceding the fibrinopeptide cleavage sites.
DISCUSSION
Reversible activation of the ProT catalytic site induced by SC-(1-325) allowed the development of novel, active site-specifically labeled ProT analogs as tools for quantifying SC interactions for the first time. Various thiol-reactive fluorescence probes were covalently linked to the catalytic Ser 195 and His 57 residues of the SC-(1-325)⅐ProT complex by a thioester derivative of FPR-CH 2 Cl. Characterization of the labeling reactions demonstrated that probe incorporation was covalent, active site-specific, and stoichiometric. Screening of 10 fluorescent ProT analogs identified the best quantitative reporters of SC-(1-325) binding. Previous studies indicated that SC bound to ProT with a 1:1 stoichiometry (1, 4, 43, 44) , but because of the apparent high affinity of the interaction, it was not possible to obtain accurate estimates of the dissociation constant ( Stability studies of mixtures of ProT and SC previously found that these mixtures converted Pro to Pre 1, releasing fragment 1 (3, 28, 45) . Our studies confirm that Pre 1 is generated initially, but in addition demonstrate that Pre 2Ј is generated more slowly. Reactions of ProT with saturating concentrations of SC-(1-325) resulted in conversion of ProT to Pre 1 and Pre 2Ј by cleavage of the two thrombin-sensitive bonds at Arg 155 -Ser 156 and Arg 284 -Thr 285 (ProT numbering), respectively. Pre 2Ј generation as a result of SC-(1-325)⅐ProT binding has not been previously reported. At saturating levels of SC-(1-325), the SC-(1-325)⅐native and labeled ProT complexes were completely cleaved, suggesting that the active complex catalyzed cleavage of other complexes. The mechanism underlying this observation is not known, but conversion of ProT to Pre 1 and Pre 2Ј may play a role in the mechanism of fibrin formation by SC. Although sedimentation equilibrium studies indicate that the SC-(1-325)⅐Pre 2 and SC-(1-325)⅐␣-thrombin complexes were not detectably dimeric under these experimental conditions (29) , there is apparently some interaction between SC-(1-325)⅐ProT complexes.
Because . Before SC-(1-325) binding, the probe could well make contact with the side chain of Trp 148 of thrombin, which in some previous FPR-thrombin structures is defined (11) (12) (13) 49) but which in several other thrombin structures is (together with the whole 148 loop) flexible. The 148 loop in the SC-(1-325)⅐(pre)thrombin complexes is trapped in the SC-(1-325) groove of D1, and the mercury ion is only 2.9 Å away from one of both SC Asp 106 carboxylate oxygens, thus in ion bond distance. From these observations and the weakening of the affinity for D1 by the presence of the probe, it is apparent that direct contact of SC-(1-325) with the probe and/or the possible interaction and movement of the 148 loop likely account for the fluorescence changes observed for the fluorescein derivatives and some of the other probes. It is important to note that this is not the case for all of the probes, however, because, for example, [ANS]FPR-ProT shows large spectral changes accompanying proteolytic activation to thrombin, whereas the fluorescein-ProT derivative does not. 7 A very similar probe-specific effect is observed for active site fluorescein-labeled plasminogen, which reports SK binding but not activation to plasmin, whereas the ANS derivative reports proteolytic activation and SK binding with similar, large spectral changes (35) . 8 This effect is not limited to cofactor-zymogen binding, because interactions for which arrays of probes have been examined, including SK with plasmin (37) and thrombin with exosite I and II ligands (41, 50) , show similarly diverse behavior. For the interactions studied thus far with multiple probes, there is no significant correlation of their signaling with bulk solution properties of the probes, such as the dependence on dielectric constant. The highly structured microenvironment of the probes and the structures of the probes themselves appear to place them in slightly different locations, resulting in idiosyncratic fluorescence changes on SC or SK binding to their respective zymogens, which allows them to report different molecular events. This is evident by the results for the highly polarity-sensitive probes, ACR and BAD, which showed a large fluorescence enhancement and essentially no change, respectively, accompanying SC-(1-325) binding. These probes differ only in an additional methylene group in the linker connecting the probe to the thiol group of the inhibitor peptide. On this basis, it can be expected that subtle changes in the probe microenvironment, established in part by the probe itself, the intrinsic spectral properties of the probes, and the reporting of different structural changes mediated by direct contact and transmitted by conformational changes dictate the observed spectral changes for various interactions. At present, there is no clear basis from the structures or spectral properties of the probes to support a detailed explanation of the differences observed or their predictability.
Development of fluorescent ProT analogs enabled quantitative analysis of SC-(1-325) interactions reported by changes in probe fluorescence intensity because of changes in the microenvironment of the active site-bound probes. These probe fluorescence changes showed a complex and sensitive dependence on probe structure as well as spectral properties. The versatility of the labeling approach allows selecting the best derivatives for characterizing interactions of ProT by fluorescence intensity, resonance energy transfer, and anisotropy changes. Although the purpose here was to characterize SC-(1-325) interactions, [ANS]FPR-ProT and likely other fluorescent derivatives report activation of ProT by the factor Xa⅐factor Va, prothrombinase complex, 7 which should enable fluorescence studies of prothrombinase complex interactions and prothrombin activation. Finally, the use of expression of a unique thiol group as the basis for active site labeling allows specific labeling with other types of spectroscopic probes, heavy atom labeling (1), active site-specific immobilization (18) , and affinity ligand labeling. These derivatives should provide valuable new tools for investigating ProT interactions and the mechanism of activation of ProT by both physiologic and pathologic activators.
